Alfonso E. Bello

1.8k total citations
24 papers, 1.4k citations indexed

About

Alfonso E. Bello is a scholar working on Pharmacology, Surgery and Rheumatology. According to data from OpenAlex, Alfonso E. Bello has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pharmacology, 8 papers in Surgery and 7 papers in Rheumatology. Recurrent topics in Alfonso E. Bello's work include Inflammatory mediators and NSAID effects (19 papers), Osteoarthritis Treatment and Mechanisms (6 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). Alfonso E. Bello is often cited by papers focused on Inflammatory mediators and NSAID effects (19 papers), Osteoarthritis Treatment and Mechanisms (6 papers) and Helicobacter pylori-related gastroenterology studies (5 papers). Alfonso E. Bello collaborates with scholars based in United States, United Kingdom and Australia. Alfonso E. Bello's co-authors include John G. Fort, Andrew Whelton, Steffen Oesser, Joseph Puma, Diane E. Normandin, William B. White, Robert J. Holt, Jay L. Goldstein, Carl B. Wallemark and Naurang M. Agrawal and has published in prestigious journals such as Gastroenterology, The American Journal of Medicine and The American Journal of Cardiology.

In The Last Decade

Alfonso E. Bello

23 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alfonso E. Bello United States	14	928	334	327	220	218	24	1.4k
William W. Zhao United States	14	1.3k 1.4×	316 0.9×	323 1.0×	145 0.7×	484 2.2×	16	1.7k
Patrizia Di Gregorio Italy	14	396 0.4×	53 0.2×	353 1.1×	81 0.4×	165 0.8×	28	915
Melissa V. Chan United Kingdom	20	199 0.2×	52 0.2×	459 1.4×	286 1.3×	204 0.9×	44	1.3k
A. Buntinx Belgium	14	357 0.4×	39 0.1×	122 0.4×	81 0.4×	184 0.8×	23	1.0k
Vane United Kingdom	16	454 0.5×	28 0.1×	230 0.7×	243 1.1×	142 0.7×	51	1.0k
M.A. Barradas United Kingdom	23	202 0.2×	48 0.1×	460 1.4×	124 0.6×	395 1.8×	72	1.7k
Maurizio Degan Italy	20	184 0.2×	42 0.1×	345 1.1×	185 0.8×	165 0.8×	58	1.2k
J. P. Famaey Belgium	15	285 0.3×	65 0.2×	56 0.2×	51 0.2×	51 0.2×	36	611
Norishi Ueda Japan	20	122 0.1×	65 0.2×	106 0.3×	79 0.4×	165 0.8×	37	1.8k
Erkki Seppälä Finland	16	250 0.3×	38 0.1×	157 0.5×	92 0.4×	101 0.5×	60	872

Countries citing papers authored by Alfonso E. Bello

Since Specialization

Citations

This map shows the geographic impact of Alfonso E. Bello's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfonso E. Bello with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfonso E. Bello more than expected).

Fields of papers citing papers by Alfonso E. Bello

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfonso E. Bello. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfonso E. Bello. The network helps show where Alfonso E. Bello may publish in the future.

Co-authorship network of co-authors of Alfonso E. Bello

This figure shows the co-authorship network connecting the top 25 collaborators of Alfonso E. Bello. A scholar is included among the top collaborators of Alfonso E. Bello based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfonso E. Bello. Alfonso E. Bello is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Francis‐Sedlak, Megan, Brian LaMoreaux, Lissa Padnick‐Silver, Robert J. Holt, & Alfonso E. Bello. (2020). Characteristics, Comorbidities, and Potential Consequences of Uncontrolled Gout: An Insurance-Claims Database Study. Rheumatology and Therapy. 8(1). 183–197. 16 indexed citations

Tive, Leslie, Alfonso E. Bello, Thomas J. Schnitzer, et al.. (2019). <p>Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip</p>. Journal of Pain Research. Volume 12. 975–995. 43 indexed citations

Bello, Alfonso E., et al.. (2017). Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatology Research and Reviews. Volume 9. 67–79. 81 indexed citations

Holt, Robert J., John G. Fort, Amy Grahn, Jeffrey D. Kent, & Alfonso E. Bello. (2015). Onset and durability of pain relief in knee osteoarthritis: Pooled results from two placebo trials of naproxen/esomeprazole combination and celecoxib. The Physician and Sportsmedicine. 43(3). 200–212. 12 indexed citations

Bello, Alfonso E., Jeffrey D. Kent, & Robert J. Holt. (2015). Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons. The Physician and Sportsmedicine. 43(3). 193–199. 6 indexed citations

Bello, Alfonso E. & Robert J. Holt. (2014). Cardiovascular Risk with Non-steroidal Anti-inflammatory Drugs: Clinical Implications. Drug Safety. 37(11). 897–902. 30 indexed citations

Ekman, Evan F., Joseph Gimbel, Alfonso E. Bello, et al.. (2014). Efficacy and Safety of Intravenous Tanezumab for the Symptomatic Treatment of Osteoarthritis: 2 Randomized Controlled Trials versus Naproxen. The Journal of Rheumatology. 41(11). 2249–2259. 71 indexed citations

Bello, Alfonso E., Jeffrey D. Kent, Amy Grahn, Patricia Rice, & Robert J. Holt. (2014). Risk of Upper Gastrointestinal Ulcers in Patients With Osteoarthritis Receiving Single-Tablet Ibuprofen/Famotidine Versus Ibuprofen Alone: Pooled Efficacy and Safety Analyses of Two Randomized, Double-Blind, Comparison Trials. Postgraduate Medicine. 126(4). 82–91. 9 indexed citations

Bello, Alfonso E., Amy Grahn, Julie Ball, Jeffrey D. Kent, & Robert J. Holt. (2014). One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension. Current Medical Research and Opinion. 31(3). 407–420. 5 indexed citations

10.

Goldstein, Jay L., Sharad Lakhanpal, Stanley M. Cohen, et al.. (2012). Decreased NSAID Associated Treatment Emergent Dyspepsia and Increased Patient Satisfaction Associated with Ibuprofen/Famotidine Combination Tablet: SODA Results from a 12-Month Trial. The American Journal of Gastroenterology. 107. S52–S53. 1 indexed citations

11.

Laine, Loren, Alan Kivitz, Alfonso E. Bello, et al.. (2011). Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. The American Journal of Gastroenterology. 107(3). 379–386. 75 indexed citations

12.

Goldstein, Jay L., Sharad Lakhanpal, Stanley Cohen, et al.. (2011). Long Term Safety of an NSAID With Built-in Gastroprotection for Treatment of Pain and Inflammation Related to Oa and RA: Comparative Results From Blinded and Open Label One Year Safety Trials of a Single-Tablet Combination of Ibuprofen-Famotidine. Gastroenterology. 140(5). S–585. 3 indexed citations

13.

Singh, Gurkirpal, John G. Fort, Jay L. Goldstein, et al.. (2006). Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study. The American Journal of Medicine. 119(3). 255–266. 265 indexed citations

14.

Bello, Alfonso E. & Steffen Oesser. (2006). Collagen hydrolysate for the treatment of osteoarthritis and other joint disorders:a review of the literature. Current Medical Research and Opinion. 22(11). 2221–2232. 132 indexed citations

15.

Whelton, Andrew, William B. White, Alfonso E. Bello, Joseph Puma, & John G. Fort. (2002). Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. The American Journal of Cardiology. 90(9). 959–963. 230 indexed citations

16.

Whelton, Andrew, John G. Fort, Joseph Puma, et al.. (2002). Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients. 8(15). 29 indexed citations

17.

McKenna, Frank, et al.. (2001). COX-2 Specific Inhibitors in the Management of Osteoarthritis of the Knee: A Placebo-Controlled, Randomized, Double-Blind Study. JCR Journal of Clinical Rheumatology. 7(3). 151–159. 42 indexed citations

18.

Whelton, Andrew, et al.. (2001). Cyclooxygenase-2???Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients. American Journal of Therapeutics. 8(2). 85–95. 258 indexed citations

19.

Patterson, Roy, Alfonso E. Bello, & J B Lefkowith. (1999). Immunologic tolerability profile of celecoxib. Clinical Therapeutics. 21(12). 2065–2079. 55 indexed citations

20.

Bello, Alfonso E., William E. Garrett, Hao Wang, et al.. (1997). Comparison of synovial fluid cartilage marker concentrations and chondral damage assessed arthroscopically in acute knee injury. Osteoarthritis and Cartilage. 5(6). 419–426. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact